Evidence map›Paper›PMID 39211592›Full record

ArticleJACS Au2024

Cyclic Peptides KS-133 and KS-487 Multifunctionalized Nanoparticles Enable Efficient Brain Targeting for Treating Schizophrenia.

Kotaro Sakamoto, Seigo Iwata, Zihao Jin, Lu Chen, Tatsunori Miyaoka, Mei Yamada, Kaiga Katahira, Rei Yokoyama, Ami Ono, Satoshi Asano and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACS Au, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Peptide-functionalized nanoparticles for brain-targeted therapeutics.Drug delivery and translational research · 2026
    Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kotaro SakamotoResearch & Development Department, Ichimaru Pharcos Company Limited, 318-1 Asagi, Motosu, 501-0475 Gifu, Japan.
Seigo IwataGraduate School of Advanced Science and Technology, Japan Advanced Institute of Science and Technology, 1-1 Asahidai, Nomi, 923-1292 Ishikawa, Japan.
Zihao JinLaboratory of Biopharmaceutics, Osaka University, 1-6 Yamada-oka, Suita, 565-0871 Osaka, Japan.
Lu ChenLaboratory of Biopharmaceutics, Osaka University, 1-6 Yamada-oka, Suita, 565-0871 Osaka, Japan.
Tatsunori MiyaokaLaboratory of Biopharmaceutics, Osaka University, 1-6 Yamada-oka, Suita, 565-0871 Osaka, Japan.ORCID https://orcid.org/0009-0003-7685-7780
Mei YamadaLaboratory of Biopharmaceutics, Osaka University, 1-6 Yamada-oka, Suita, 565-0871 Osaka, Japan.
Kaiga KatahiraLaboratory of Biopharmaceutics, Osaka University, 1-6 Yamada-oka, Suita, 565-0871 Osaka, Japan.
Rei YokoyamaDepartment of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553 Hiroshima, Japan.
Ami OnoDepartment of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553 Hiroshima, Japan.
Satoshi AsanoDepartment of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553 Hiroshima, Japan.
Kotaro TanimotoDepartment of Orthodontics and Craniofacial Developmental Biology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553 Hiroshima, Japan.
Rika IshimuraCenter for Supporting Drug Discovery and Life Science Research, Graduate School of Pharmaceutical Science, Osaka University, 1-6 Yamada-oka, Suita, 565-0871 Osaka, Japan.
Shinsaku NakagawaLaboratory of Biopharmaceutics, Osaka University, 1-6 Yamada-oka, Suita, 565-0871 Osaka, Japan.
Takatsugu HirokawaDivision of Biomedical Science, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575 Tsukuba, Japan.ORCID https://orcid.org/0000-0002-3180-5050
Yukio AgoLaboratory of Biopharmaceutics, Osaka University, 1-6 Yamada-oka, Suita, 565-0871 Osaka, Japan.
Eijiro MiyakoGraduate School of Advanced Science and Technology, Japan Advanced Institute of Science and Technology, 1-1 Asahidai, Nomi, 923-1292 Ishikawa, Japan.ORCID https://orcid.org/0000-0002-1157-6174

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Establishing drug delivery systems (DDSs) for transporting drugs from peripheral tissues to the brain is crucial for treating central nervous system diseases. We previously reported the interactions of (1) KS-133, a selective antagonist peptide, with vasoactive intestinal peptide receptor 2 (VIPR2), a drug target for schizophrenia, and (2) KS-487, a selective binding peptide, with the cluster IV domain of low-density lipoprotein receptor-related protein 1 (LRP1), which is involved in crossing the blood-brain barrier. We developed a novel DDS-based strategy for treating schizophrenia using KS-487 as a brain-targeting peptide and KS-133 as a drug. Dibenzocyclooctyne-KS-487 was conjugated with N

Identifiers

PMID39211592
PMCPMC11350716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.